COMPANY

General Oncology

HQ: Newton, MA source · generaloncology.com ↗ · New England

Keywords: oncology Pancreatic Adenocarcinoma Metastatic BRCA1 Mutation BRCA2 Mutation Pancreatic Acinar Cell Carcinoma Pancreatic Ductal Adenocarcinoma Pancreatic Cancer Metastatic Pancreatic Cancer Metastatic Pancreatic Ductal Adenocarcinoma Breast Cancer Metastatic Breast Cancer Stage IV Pancreatic Cancer Stage IV HER2-negative Breast Cancer HER2 Negative Breast Carcinoma Adenocarcinoma of the Breast PALB2 Gene Mutation Metastatic Pancreas Cancer Recurrent Pancreas Cancer Pancreas Cancer Stage IV Pancreatic Cancer Vitamin B12B

Location: Newton, MA · source · Oct 14, 2026

Profile checked Oct 10, 2026

1Trials (company is sponsor)

Funding and NIH signals

SEC Form D raise Raised $4.81M (Form D filed Apr 23, 2026). SEC Form D 0001658021-26-000006 (Apr 23, 2026)
Evidence (1 event)
- Apr 23, 2026 · SEC Form D 0001658021-26-000006
  Name of Issuer: General Oncology, Inc.; CIK: 1658021; Address: Newton, MA; Submission type: D; Filing date: 2026-04-23; Industry Group: Pharmaceuticals; Date of First Sale: 2026-04-15; Types of Securities Offered: Option/warrant, Other (Simple Agreement for Future Equity (SAFE), the shares of Issuer capital stock into which the SAFE may convert (SAFE Shares), and the shares of Issuer capital stock into which the SAFE Shares may convert.); Business combination transaction: false; Total Offering Amount: 4805299; Total Amount Sold: 4805299; Federal exemptions: 06b

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

Jan 13, 2021 Trial start Phase 1: SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells source ↗

Upcoming milestones

2028-12 (ESTIMATED) · Phase 1 · SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells · NCT04150042

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 1

Record	Title	Phase	Status	Start	Primary completion
NCT04150042	SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells	Phase 1	Recruiting	Jan 13, 2021	2028-12 (estimated)